- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05355610
Vestibular Rehabilitation With Intratympanic Drug Therapy in Meniere's Disease
Objective Vestibular Evaluation & Rehabilitation With Intratympanic Dexamethasone and Gentamicin in Meniere's Disease
Intractable symptoms of Meniere's disease will be treated with intratympanic steroids.
At the same time intratympanic dexamethasone will be used to rescue hearing
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
For Alleviation of Intractable symptoms of Meniere's disease will be treated with intratympanic steroids. Measured with pre and post therapy vestibular severity index.
At the same time intratympanic dexamethasone will be used to rescue hearing measured with speech reception threshold and speech discrimination threshold
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Zeeshan Ayub, FCPS
- Phone Number: +923215233648
- Email: zeeshanent@yahoo.com
Study Contact Backup
- Name: Zeeshan Ayub, FCPS
- Phone Number: 03215233648
- Email: zeeshanent@yahoo.com
Study Locations
-
-
Balochistan
-
Quetta, Balochistan, Pakistan, 87300
- Recruiting
- Cmh Quetta
-
Contact:
- Zeeshan Ayub, FCPS
- Phone Number: +923215233648
-
Contact:
- Azeema Ahmed, FCPS
- Phone Number: +923325222335
- Email: azeemazeeshan1980@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients of unilateral Meniere's disease with severe vestibular symptoms
Exclusion Criteria:
- Bilateral disease, operated cases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vestibular severity index improvement
Improvement in vestibular symptoms with intratympanic gentamicin
|
Intratympanic gentamicin and dexamethasone administered in two doses one week apart
Other Names:
Intratympanic gentamicin and dexamethasone administered in two doses one week apart
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vestibular Rehabilitation
Time Frame: Three months
|
Improvement in vestibular severity index
|
Three months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Zeeshan Ayub, FCPS, Cmh Quetta
- Study Chair: Zeeshan Ayub, FCPS, Cmh Quetta
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Otorhinolaryngologic Diseases
- Labyrinth Diseases
- Ear Diseases
- Endolymphatic Hydrops
- Vestibular Diseases
- Meniere Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Dexamethasone
- Dexamethasone acetate
- BB 1101
- Gentamicins
Other Study ID Numbers
- File No: CMH QTA-IRB/043
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vestibular Disorder Preservation
-
University Hospital, Strasbourg, FranceRecruiting
-
Bern University of Applied SciencesGoethe University; Maastricht University Medical Center; Swiss Federal Institute...CompletedEquilibration Disorder, Vestibular NerveSwitzerland
-
University Hospital, CaenUnknownUnspecified Disorder of Vestibular Function, BilateralFrance
-
King's College LondonUniversity College, LondonUnknown
-
Assistance Publique Hopitaux De MarseilleUnknownVestibular DisordersFrance
-
University of JaénCompletedPeripheral Vestibular DisorderSpain
-
Cairo UniversityRecruitingPeripheral Vestibular DisordersEgypt
-
United States Naval Medical Center, San DiegoThe Geneva FoundationWithdrawnHearing and Vestibular DisordersUnited States
-
Hospital de Rehabilitacion Manuel RoccaActive, not recruitingVestibular Disease | Peripheral Vestibular DisorderArgentina
-
Ege UniversityCompletedVestibular Disorder | Peripheral Vestibular DisorderTurkey
Clinical Trials on Gentamicin
-
Johns Hopkins Bloomberg School of Public HealthDhaka Shishu HospitalCompleted
-
Kwong Wah HospitalThe Hong Kong Society of NephrologyUnknownRate of Exit Site Infection | Rate of Atypical Mycobacterial Infection | Rate of Peritoneal DialysisHong Kong
-
United States Naval Medical Center, PortsmouthCompleted
-
Diskapi Teaching and Research HospitalCompleted
-
University of Southern CaliforniaRecruitingRecessive Dystrophic Epidermolysis BullosaUnited States
-
PENTA FoundationChiesi Farmaceutici S.p.A.Completed
-
University of California, San DiegoRecruitingSepsis | Nephrolithiasis | Urinary Tract Infection (UTI)United States
-
Penang Hospital, MalaysiaThe Queen Elizabeth Hospital; Enche' Besar Hajjah Khalsom Hospital; Jasin Hospital and other collaboratorsCompleted
-
University of Southern CaliforniaRecruiting
-
Stanford UniversityDavid Drover, MDCompletedDrug Metabolism During PregnancyUnited States